TIB200 is a gel to provide topical pain relief. The product incorporates a non-steroidal anti-inflammatory drug ("NSAID") ibuprofen and utilises Futura's DermaSys® technology.
Our unique transdermal technology - DermaSys®
Futura has developed a highly efficient and proprietary delivery technology, DermaSys® for the absorption of active molecules through the skin. DermaSys® is a versatile and bespoke technology in that it can be tailored to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile reducing the risk of side effects due to a lower systemic uptake.
Market-leading clinical trial results
In early in vitro studies and more recently in an in vivo clinical study DermaSys® showed significant superiority in terms of skin penetration of the NSAID molecule. TIB200, a topical gel combining the well-known analgesic ibuprofen with the DermaSys® delivery system, has been shown to achieve up to twenty times higher penetration through human skin compared against other commercially available topical ibuprofen gels.
In a recent clinical study to assess the efficacy and safety against a market-leading ibuprofen gel, oral ibuprofen as well as a placebo gel, TIB200 not only achieved its primary efficacy endpoint against placebo but also outperformed both the topical and oral comparators.
Our objective is for our products to be "best-in-class" against other comparable topical products. The rationale for this is that the National Institute for Health and Care Excellence (NICE) gives clear guidance to healthcare professionals to prescribe topical NSAIDs in the first instance for joint pain associated with osteoarthritis, in preference to oral NSAIDs, owing to concerns over systemic side effects caused by the long term use of oral NSAIDs.
We are progressing with the development work. In 2016, we retained advisors to assist in the out-licensing of TIB200. Both TIB200 and TPR100 have attracted considerable interest from major pharmaceutical and consumer healthcare companies. We continue to be in discussions regarding further potential regional licensing deals in 2017.
Protecting our IP
Futura has both granted patents and a number of further patent applications in relation to its DermaSys® technologies providing protection to at least 2028.